Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.
Hundreds of potential kidney donors of Black African and Black Caribbean heritage in the UK can now get a simple blood test to help reduce the risk of kidney failure.